Please assess the completion status of the following clinical trial:

Trial Title: Role of Coumadin in Preventing Thromboembolism in Atrial Fibrillation (AF) Patients Undergoing Catheter Ablation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age- 18-75 years~2. Patients in paroxysmal, persistent or long-standing persistent (LSP) AF~3. patients with CHADS2 score ≥ 1~4. AF patients with INR in the range of 2.0-3.0 in the last 3-4 weeks prior to ablation~Exclusion Criteria:~1. Patients with known bleeding disorders or inherited thrombophilic disorder~2. Patients with oral contraceptives or estrogen replacement therapy~3. Patients with prosthetic heart valves~4. Patients unable or willing to give informed consent~5. Contraindications for Coumadin therapy~6. Patients with CHADS2 score zero~7. Contraindication to undergoing an MRI

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Study Arm (Type: ACTIVE_COMPARATOR): Patients receive continuous Coumadin therapy throughout the study.
- Control Arm (Type: ACTIVE_COMPARATOR): Patients discontinue Coumadin 3-4 days prior to ablation and replace it with heparin until the end of the procedure and bridge low molecular weight heparin (LMWH) with Coumadin 48-72 hours after ablation.

Based on this trial design, predict the completion outcome and termination type (if applicable).